Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis.
We sought to describe the safety profile of open-label, adjunctive deferasirox iron chelation therapy in eight patients with biopsy-proven mucormycosis. Deferasirox was administered for an average of 14 days (range, 7 to 21) at 5 to 20 mg/kg of body weight/day. The only adverse effects attributable to deferasirox were rashes in two patients. Deferasirox treatment was not associated with changes in renal or liver function, complete blood count, or transplant immunosuppressive levels. Thus, deferasirox appears safe as an adjunctive therapy for mucormycosis.
Spellberg
Brad
B
Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, 1124 West Carson St., Torrance, CA 90502, USA. bspellberg@labiomed.org
Andes
David
D
Perez
Mario
M
Anglim
Anne
A
Bonilla
Hector
H
Mathisen
Glenn E
GE
Walsh
Thomas J
TJ
Ibrahim
Ashraf S
AS
D000328:Adult; D000368:Aged; D001565:Benzoates / Q000009:adverse effects* / Q000627:therapeutic use*; D015913:Chelation Therapy; D000077588:Deferasirox; D005076:Exanthema / Q000139:chemically induced; D005260:Female; D006801:Humans; D007502:Iron Chelating Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009091:Mucormycosis / Q000188:drug therapy*; D016896:Treatment Outcome; D014230:Triazoles / Q000009:adverse effects* / Q000627:therapeutic use*
D001565:Benzoates; D007502:Iron Chelating Agents; D014230:Triazoles; D000077588:Deferasirox